Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A1 | O15245 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.44 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | ESR1 | P03372 | 2/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrabuthylammonium SCHEMBL28117120 | 0.98 | CYP3A4 (0.48) | SLC22A1CYP3A4TDP1SLC22A2DNM1 | |
| Tetrabuthylammonium SCHEMBL28255036 | 0.98 | SLC22A1 (0.48) | SLC22A1CYP3A4TDP1SLC22A2DNM1 | |
| Tetrabuthylammonium SCHEMBL3832727 | 0.98 | CYP3A4 (0.48) | SLC22A1CYP3A4TDP1SLC22A2DNM1 | |
| Tetrabuthylammonium SCHEMBL28169460 | 0.96 | SLC22A1 (0.46) | SLC22A1CYP3A4TDP1SLC22A2DNM1 | |
| Tetrabuthylammonium SCHEMBL9800016 | 0.94 | SLC22A1 (0.44) | SLC22A1CYP3A4TDP1SLC22A2DNM1 | |
| Heptane SCHEMBL28144929 | 0.89 | CYP3A4 (0.57) | CYP3A4TDP1DNM1TP53SMN1; SMN2 | |
| Hexane SCHEMBL22129187 | 0.89 | CYP3A4 (0.63) | CYP3A4TDP1DNM1TP53SMN1; SMN2 | |
| Tetrabuthylammonium SCHEMBL7636163 | 0.88 | SLC22A1 (0.46) | SLC22A1CYP3A4SLC22A2DNM1TP53 | |
| Hexane SCHEMBL7758441 | 0.87 | CYP3A4 (0.60) | CYP3A4TDP1DNM1TP53SMN1; SMN2 | |
| Heptane SCHEMBL28244261 | 0.87 | CYP3A4 (0.60) | CYP3A4TDP1DNM1TP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119654353-A | Compound, curable resin composition, and cured product thereof | 日本化药株式会社 | 2025-03-18 | — | — | CN | disclosed |
| CN-119278222-A | Curable resin composition, resin sheet, and cured product | 日本化药株式会社 | 2025-01-07 | — | — | CN | disclosed |
| CN-118974107-A | Maleimide compound, curable resin composition, cured product thereof, amine compound, and reactant of amine compound and maleic anhydride | 日本化药株式会社 | 2024-11-15 | — | — | CN | disclosed |
| CN-117279962-B | Maleimide resin, curable resin composition, and cured product thereof | 日本化药株式会社 | 2024-11-01 | — | — | CN | disclosed |
| CN-118401587-A | Curable resin composition, resin sheet, and cured product thereof | 日本化药株式会社 | 2024-07-26 | — | — | CN | disclosed |
| CN-117321091-B | Maleimide resin, amine resin, curable resin composition, and cured product thereof | 日本化药株式会社 | 2024-06-04 | — | — | CN | disclosed |
| WO-2023074259-A1 | AMINE COMPOUND, MALEIMIDE COMPOUND, CURABLE RESIN COMPOSITION, AND CURED PRODUCT THEREOF | 日本化薬株式会社 | 2023-05-04 | — | — | WO | disclosed |
| WO-2023063122-A1 | CURABLE RESIN COMPOSITION, PREPREG, AND CURED PRODUCT OF SAME | 日本化薬株式会社 | 2023-04-20 | — | — | WO | disclosed |
| WO-2022239811-A1 | MALEIMIDE RESIN, AMINE RESIN, CURABLE RESIN COMPOSITION, AND CURED PRODUCT THEREOF | 日本化薬株式会社 | 2022-11-17 | — | — | WO | disclosed |
| WO-2022234829-A1 | MALEIMIDE RESIN, CURABLE RESIN COMPOSITION, AND CURED PRODUCT THEREOF | 日本化薬株式会社 | 2022-11-10 | — | — | WO | disclosed |
| WO-2022186030-A1 | COMPOUND, MIXTURE, CURABLE RESIN COMPOSITION, AND CURED PRODUCT THEREOF | 日本化薬株式会社 | 2022-09-09 | — | — | WO | disclosed |
| WO-2022181758-A1 | CURABLE RESIN COMPOSITION, PREPREG, AND CURED PRODUCT OF SAME | 日本化薬株式会社 | 2022-09-01 | — | — | WO | disclosed |
| US-7223374-B2 | Hydroformylation process employing a cobalt-based catalyst in a non-aqueous liquid with improved catalyst recycling | INSTITUT FRANCAIS DU PETROLE (FR) | 2007-05-29 | — | — | US | disclosed |
| US-20060128999-A1 | Hydroformylation process employing a cobalt-based catalyst in a non-aqueous liquid with improved catalyst recycling | MAGNA LIONEL | 2006-06-15 | — | — | US | disclosed |
| US-7060860-B2 | Hydroformylation process employing a cobalt-based catalyst in a non-aqueous liquid with improved catalyst recycling | INSTITUT FRANCAIS DU PETROLE (FR) | 2006-06-13 | — | — | US | disclosed |
| US-20030225303-A1 | Hydroformylation process employing a cobalt-based catalyst in a non-aqueous liquid with improved catalyst recycling | INSTITUT FRANCAIS DU PETROLE (FR) | 2003-12-04 | — | — | US | disclosed |
| US-6410799-B1 | LIQUID PHASE HEATING | INSTITUT FRANCAIS DU PETROLE (FR) | 2002-06-25 | — | — | US | disclosed |
| US-20020035297-A1 | Hydroformylation process employing a catalyst based on cobalt and/or rhodium in a non-aqueous ionic solvent | INSTITUT FRANCAIS DU PETROLE (FR) | 2002-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035297-A1 | Hydroformylation process employing a catalyst based on cobalt and/or rhodium in a non-aqueous ionic solvent | NUDT1, IDH1, HRH4 | SLC22A1 2834/4885CYP3A4 1859/4885TDP1 3830/4885 |
| US-20060128999-A1 | Hydroformylation process employing a cobalt-based catalyst in a non-aqueous liquid with improved catalyst recycling | AP2S1, NUDT1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | SLC22A1 2942/4885CYP3A4 3312/4885TDP1 3788/4885 |
| US-20030225303-A1 | Hydroformylation process employing a cobalt-based catalyst in a non-aqueous liquid with improved catalyst recycling | NUDT1, AP2S1, SRSF1 | SLC22A1 3099/4885CYP3A4 3120/4885TDP1 3606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.